Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: Potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis

Journal of Medicinal Chemistry

Volumn 49, Issue 7, 2006, Pages 2222-2231

  Voets, Marieke ^a   Antes, Iris ^b   Scherer, Christiane ^a   Müller Vieira, Ursula ^a   Biemel, Klaus ^c   Marchais Oberwinkler, Sandrine ^a   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^c Pharmacelsus CRO   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHOXYINDENE; 6 METHOXYDIHYDRONAPHTHALENE; ALDOSTERONE SYNTHASE; ALDOSTERONE SYNTHASE INHIBITOR; AROMATASE; CYTOCHROME P450 11B1; CYTOCHROME P450 17; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; FADROZOLE; INDENE DERIVATIVE; KETOCONAZOLE; NAPHTHALENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN CACO 2; CONGESTIVE HEART FAILURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HEART MUSCLE FIBROSIS; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; MOLECULAR DYNAMICS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ALDOSTERONE SYNTHASE; ANIMALS; BINDING SITES; CELL LINE; CELL MEMBRANE PERMEABILITY; CRICETINAE; CRICETULUS; FIBROSIS; HEART FAILURE, CONGESTIVE; HUMANS; INDENES; MODELS, MOLECULAR; MYOCARDIUM; NAPHTHALENES; SCHIZOSACCHAROMYCES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33645662194     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060055x     Document Type: Article

References (43)

1. Kawamoto, T.; Mitsuuchi, Y.; Toda, K., Yokoyama, Y.; Miyakara, K.; Miura, S.; Onishi, T.; Ichihawa, Y.; Nakao, K.; Imura, H.; Ulick, S.; Shizuta, Y. Role of steroid 11β-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 1458-1462.
2. Gomez-Sanchez, C. E.; Zhou, M. Y.; Cozza, E. N.; Morita, H.; Foecking, M. F.; Gomez-Sanchez, E. P. Aldosterone biosynthesis in the rat brain. Endocrinology 1997, 138, 3369-3373.
3. Hatakeyama, H.; Miyamori, I.; Fujita, T.; Takeda, Y.; Takeda, R.; Yamamoto, H. Vascular aldosterone. J. Biol. Chem. 1994, 269, 24316-24320.
4. White, P. C. Aldosterone: Direct effects on and production by the heart. J. Clin. Endocrinol. Metab. 2003, 88, 2376-2383.
5. Satoh, M.; Nakamura, M.; Saitoh, H.; Satoh, H.; Akatsu, T.; Iwasaka, J.; Masuda, T.; Hiramori, K. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin. Sci. 2002, 102, 381-386.
6. Sylvestre, J.-S.; Robert, V.; Heymes, C.; Aupetit-Faisant, B.; Mouas, C.; Moalic, J.-M.; Swynghedauw, B.; Delcayre, C. Myocardial production of aldosterone and corticosterone in the rat. J. Biol. Chem. 1998, 273, 4883-4891.
7. Pitt, B.; Zannad, F.; Remme, W. J.; Cody, R.; Castaigne, A.; Perez, A., Palensky, J.; Wittes, J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999, 341, 709-717.
8. Pitt, B.; Remme, W. J.; Zannad, F.; Neaton, J.; Martinez, F.; Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348, 1309-21.
9. Khan, N. U. A.; Movahed, A. The role of aldosterone and aldosterone-receptor antagonists in heart failure. Rev. Cardiovasc. Med. 2004, 5, 71-81.
10. Juurlink, D. N.; Mamdani, M. M.; Lee, D. S.; Kopp, A.; Austin, P. C.; Laupacis, A.; Redelmeier, D. A. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 2004, 351, 543-551.
11. Hartmann, R. W. Selective inhibition of steroidogenic P450 enzymes: current status and future perspectives. Eur. J. Pharm. Sci. 1994, 2, 15-16.
12. Ehmer, P. B.; Bureik, M.; Bernhardt, R.; Müller, U.; Hartmann, R. W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): Screening in fission yeast and evaluation of selectivity in V79 cells. J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179.
13. Hartmann, R. W.; Müller, U.; Ehmer, P. B. Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis. Eur. J. Med. Chem. 2003, 38, 363-366.
14. Taymans, S. E.; Pack, S.; Pak, E.; Torpy, D. J.; Zhuang, Z.; Stratakis, C. A. Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J. Clin. Endocrinol. Metab. 1998, 83, 1033-1036.
15. Voets, M.; Müller-Vieira, U.; Marchais-Oberwinkler, S.; Hartmann, R. W. Synthesis of amidinohydrazones and evaluation of their inhibitory effect towards aldosterone synthase (CYP11B2) and the formation of selected steroids. Arch. Pharm. Pharm. Med. Chem. 2004, 337, 411-416.
16. Ulmschneider, S.; Müller-Vieira, U.; Mitrenga, M.; Hartmann, R. W.; Oberwinkler-Marchais, S.; Klein, C. D.; Bureik, M.; Bernhardt, R.; Antes, I.; Lengauer, T. Synthesis and evaluation of imidazolylmethylene- tetrahydronaphthalenes and imidazolylmethylene-indanes: Potent inhibitors of aldosterone synthase. J. Med. Chem. 2005, 48, 1796-1805.
17. Ulmschneider, S.; Müller-Vieira, U.; Klein, C. D.; Antes, I.; Lengauer, T.; Hartmann, R. W. Synthesis and evaluation of (pyridylmethylene)- tetrahydronaphthalenes/-indanes and structurally modified derivatives: Potent and selective inhibitors of aldosterone synthase. J. Med. Chem. 2005, 48, 1563-1575.
18. Voets, M.; Antes, I.; Scherer, C.; Müller-Vieira, U.; Biemel, K.; Barassin, C.; Oberwinkler-Marchais, S.; Hartmann, R. W. Heteroaryl substituted naphthalenes and structurally modified derivatives: Selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J. Med. Chem. 2005, 48, 6632-6642.
19. Miyaura, N.; Suzuki, N. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
20. Bencze, W. L.; Barsky, L. I. Selective adrenal cortical and gonadal inhibitors. J. Med. Pharm. Chem. 1962, 5, 1298-1306.
21. 2 synthase inhibitors. Eur. J. Med. Chem. 1991, 26, 423-433.
22. Häusler, A.; Monnet, G.; Borer, C.; Bhatnagar, A. S. Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis in the rat adrenal. J. Steroid Biochem. 1989, 34, 567-570.
23. Demers, L. M.; Melby, J. C.; Wilson, T. E.; Lipton, A.; Harvey, H. A.; Santen, R. J. The effects of CGS 16949A, an aromatase inhibitor, on adrenal mineralocorticoid biosynthesis. J. Clin. Endocrinol. Metab. 1990, 70, 1162-1166.
24. Denner, K.; Doehmer, J.; Bernhardt, R. Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 Chinese hamster cells. Endocr. Res. 1995, 21, 443-448.
25. Thompson, E. A.; Siiteri, P. K. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J. Biol. Chem. 1974, 249, 5364-5372.
26. Hartmann, R. W.; Batzl, C. Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl) piperidine-2,6-diones. J. Med. Chem. 1986, 29, 1362-1369.
27. 17.20-lyase (P450c17) by coexpression of P450c17 with NADPH-cytochrome-P450-reductase in Escherichia coli. J. Steroid Biochem. Mol. Biol. 2000, 75, 57-63.
28. Hutschenreuter, T. U.; Ehmer, P. B.; Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent nonsteroidal CYP17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant enzyme. J. Enzyme Inhib. Med. Chem. 2004, 19, 17-32.
29. Yee, S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in men-fact or myth. Pharm. Res. 1997, 14, 763-766.
30. Tannergren, C.; Langguth, P.; Hoffmann, K. J. Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity. Pharmazie 2001, 56, 337-342.
31. Laitinen, L.; Kangas, H.; Kaukonen, A. M.; Hakala, K.; Kotiaho, R.; Kostiainen, R.; Hirvonen, J. N-in-one permeability studies of heterogeneous sets of compounds across Caco-2 cell monolayers. Pharm. Res. 2003, 20, 187-197.
32. Saito, H.; Fukasawa, Y.; Otsubo, Y.; Yamada, K.; Sezaki, H.; Yamashita, S. Carrier-mediated transport of macrolide antimicrobial agents across Caco-2 cell monolayers. Pharm. Res. 2000, 17, 761-765.
33. Fiebeler, A.; Nussberger, J.; Shagdarsuren, E.; Rong, S.; Hilfenhaus, G.; Al-Saadi, N.; Dechend, R.; Wellner, M.; Meiners, S.; Maser-Gluth, C.; Jeng, A. Y.; Webb, R. L.; Luft, F. C.; Muller, D. N. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005, 111, 3087-3094.
34. Lindley, W. A.; MacDowell, D. W. H. Keto-enol tautomerism in the thiophene analogues of naphthacen-5-one. J. Org. Chem. 1982, 47, 705-709.
35. Hauser, C. R.; Skell, P. S.; Bright, R. D.; Renfrew, W. B. Removal of hydrogen bromide from certain β-phenylalkyl bromides by means of potassium amide in liquid ammonia. J. Am. Chem. Soc. 1947, 69, 589-593.
36. Li, W.; Nelson, D. P.; Jensen, M. S.; Hoerrner, R. S.; Cai, D.; Larsen, R. D.; Reider, P. J. An improved protocol for the preparation of 3-pyridyl- and some arylboronic acids. J. Org. Chem. 2002, 67, 5394-5397.
37. Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Matak Vinkovic, D.; Jhoti, H. Crystal structure of human cytochrome P4502C9 with bound warfarin. Nature 2003, 424, 464-468.
38. Hindle, S. A.; Rarey, M.; Buning, C.; Lengauer, T. Flexible docking under pharmacophore type constraints. J. Comput.-Aided Mol. Des. 2002, 16, 129-149.
39. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
40. Rarey, M.; Kramer, B.; Lengauer, T. Multiple automatic base selection: Protein-ligand docking based on incremental construction without manual intervention. J. Comput.-Aided Mol. Des. 1997, 11, 369-384.
41. Scott, W. R. P.; Hünenberger, P. H.; Tironi, I. G.; Mark, A. E.; Billeter, S. R.; Fennen, J.; Torda, A. E.; Huber, T.; Krüger, P.; van Gunsteren, W. F. The GROMOS Biomolecular Simulation Program Package. J. Phys. Chem. A 1999, 103, 3596-3607.
42. Lindahl, E.; Hess, B.; van der Spoel, D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J. Mol. Mod. 2001, 7, 306-317.
43. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; Hermans, J. Interaction models for water in relation to protein hydration. In Intermolecular Forces; Pullman, B., Ed.; Reidel Publishing Co.: Dordrecht, The Netherlands, 1981; pp 331-342.